AcquisitionOther
Lyell Immunopharma, Inc. acquired ImmPACT Bio USA Inc
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Lyell Immunopharma, Inc. -> ImmPACT Bio USA Inc
The acquisition strengthens Lyells clinical-stage pipeline of CAR T-cell therapies and complements its suite of innovative technologies designed to generate longer-lasting, functional T cells to achieve more durable outcomes for patients.
Open source record (SEC) ↗